Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUN 22 ... using a new, proprietary, low-dose formulation of bromfenac, the active ingredient in Xibrom(R) (bromfenac ophthalmic solution) 0.09%. The study achieved statistical significance in ...
2009 FEB 2 ... results from a Phase II clinical trial studying the potential of a lower strength of Xibrom to treat the signs and symptoms of dry eye disease in the first half of 2009. Once this ...
2009 MAR 3 ... became the fastest growing and fifth largest branded ophthalmic drug company in the U.S. Xibrom continues its strong growth trajectory, and Istalol ended the year with an upswing in ...
2009 AUG 17 ... using a new, proprietary, low-dose formulation of bromfenac, the active ingredient in Xibrom. Combined with our previously announced positive Phase 2b results from ecabet sodium, we ...
2009 NOV 16 ... just begun. The ocular allergy market is the largest market we have entered to date, and Xibrom and Istalol continue to show strong growth. We believe ISTA will finish 2009 in a strong ...
2009 SEP 21 ... strongly but also enter next year with an expanded sales force in place. Bepreve and Xibrom will share the top spot on our promotional activities, but we will continue to devote ...
2009 APR 20 ... inflammation allergy, dry eye, and glaucoma. The major products of the company include Xibrom, Istalol and Vitrase. The company's Xibrom is used ...
2009 MAY 19 ... company in the U.S. based on product sales. ISTA's strong growth is due to the fact Xibrom and Istalol continue to gain market share in their respective markets. We expect both ...
2009 MAR 30 ... ketorolac 0.4% four times daily (Acular LS, Allergan) or bromfenac 0.09% twice daily (Xibrom, ISTA Pharmaceuticals) in an open label trial."
"Patients having ...
2008 MAY 12 ... retrospective case control study that was designed to evaluate the adjuvant use of Xibrom(TM) (bromfenac 0.09mg ophthalmic solution) in Lucentis(R) (ranibizumab) treatment of ...
2008 DEC 15 ... announced results from the Company's recently completed Phase III clinical program of Xibrom(TM) (0.09% bromfenac sodium ophthalmic solution) QD (once-daily). The program enrolled ...
2008 APR 21 ... of documents regarding promotional, educational and other activities relating to Xibrom(TM) (bromfenac sodium ophthalmic solution) 0.09%.
It is ISTA's policy to ...
2008 APR 14 ... Pharmaceuticals, Inc. (NASDAQ:ISTA), reported topline results of a clinical trial of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once-daily) 0.18% formulation, a new ...
2008 OCT 6 ... our Bepreve NDA expected to file by the end of the year, results anticipated from our Xibrom 0.09% once-daily Phase III program to support an early 2009 sNDA filing, and results ...
2008 MAY 14 ... same period in 2007.
"Our sales and marketing group continues to grow Xibrom and Istalol sales, up 69% and 23%, respectively, year over year. During our national ...
2008 AUG 19 ... loss of $8.7 million (or $0.32 per share) for the same period in 2007.
"Xibrom sales continued to grow strongly during the second quarter. As our commercial business ...
2008 NOV 11 ... largest branded ophthalmic pharmaceutical company position, surpassing Bausch & Lomb. Xibrom and Istalol are leading the way as the two fastest-growing ophthalmic products in the ...
